Thank you correcting @Jdmoney - I got confused by TNBC vs. breast cancer as a whole.
So, according to the analyst quoted in the same article [1], we have an estimated 4.7b in peak sales in breast cancer (read: for both mTNBC and HER-2 negative breast cancer indications). And "To justify the $21 billion acquisition price for Immunomedics, Trodelvy needs to hit around $4 billion to $5 billion in peak sales, analysts have figured".
Therefore, we have 4.7b forecast vs 4.5b to break even. That leaves Gilead with a <5% margin of error. Then, there's clinical risk, "Phase 3 data from the TROPiCS-02 trial in third-line HR-positive, HER2-negative breast cancer is expected to read out toward the end of this year, which Porges suggested could affect Trodelvy’s outlook in a big way". Another article worth a read [2] mentions that Gilead is "pretty confident" that the P3 trial will deliver, but the author had a word of caution nonetheless. One final upside, Immunomedics had other drugs in its pipeline but it seems the deal was really about Trodelvy.
This strikes me as a particularly tight deal for Gilead and a great one for Immunomedics.
[1] https://www.fiercepharma.com/marketing/gilead-snags-full-trodelvy-tnbc-nod-but-it-needs-more-to-make-21b-immunomedics-buy
[2] https://www.evaluate.com/vantage/articles/events/company-events/heat-gilead-tropics-readout-nears
General Comments / Chat, page-5184
-
- There are more pages in this discussion • 6,700 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
$1.61 | $1.62 | $1.55 | $189.9K | 121.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1316 | $1.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.59 | 34961 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1316 | 1.580 |
1 | 400 | 1.560 |
2 | 8157 | 1.550 |
1 | 6250 | 1.540 |
1 | 25000 | 1.530 |
Price($) | Vol. | No. |
---|---|---|
1.590 | 34961 | 1 |
1.595 | 3134 | 2 |
1.600 | 3000 | 1 |
1.650 | 17029 | 2 |
1.690 | 6570 | 3 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online